Please login to the form below

Not currently logged in
Email:
Password:

Teva's MS drug disappoints in trial

Teva Pharmaceutical Industries has said its oral MS drug laquinimod has failed to reach its primary endpoint in a phase III trial but the company still plans regulatory submissions in the EU and US

Teva Pharmaceutical Industries has said its oral multiple sclerosis (MS) drug laquinimod has failed to reach its primary endpoint in a phase III trial.

Compared to placebo, the therapy, which is being investigated for use in the treatment of relapsing-remitting multiple sclerosis (RRMS), did not reduce annual relapse rates of the disease.

However, Teva said there were dissimilarities in the baseline magnetic resonance imaging (MRI) characteristics of the study group receiving placebo and the study group receiving laquinimod, affecting the trial's results.

When adjusted, laquinimod demonstrated a significant reduction in relapse rate for the disease, as well as a reduced risk of disability progression and brain volume loss.

Teva said additional analyses of the study data are ongoing, and the company still has plans to submit the drug for approval in both the EU and US.

Professor Yitzhak Peterburg, Teva's group vice-president, Global Branded Products, said: "Teva remains committed to the clinical development of laquinimod and is confident that the drug could provide a unique option for the treatment of multiple sclerosis."

2nd August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics